Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-010 in Cystic Fibrosis with ΔF508 Mutation
NCT02564354Phase 1Completed
- Sponsor
- ProQR Therapeutics
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of eluforsen in cystic fibrosis (CF) (2 arms), sponsored by ProQR Therapeutics. Primary endpoint: Change From Baseline of CFTR-mediated Total Chloride Transport as Measured by Nasal Potential Difference at 7 weeks. Started Sep 2015; status: completed.
02
Drugs
eluforsen
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02564354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564354.